Market revenue in 2023 | USD 510.1 million |
Market revenue in 2030 | USD 1,050.5 million |
Growth rate | 10.9% (CAGR from 2023 to 2030) |
Largest segment | Hba1c tests |
Fastest growing segment | HGB/HCT tests |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Complete blood count, HGB/HCT tests, Basic metabolic panel, BUN creatinine tests, Electrolytes testing, HbA1c tests, Comprehensive metabolic panel tests, Liver panel tests, Renal panel tests, Lipid panel tests |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Labcorp Holdings Inc, ARUP Laboratories, OPKO Health Inc, Clinical Reference Laboratory, Sonic Healthcare Ltd, Cinven, Unilabs |
Hba1c tests was the largest segment with a revenue share of 12.86% in 2023. Horizon Databook has segmented the Saudi Arabia clinical laboratory tests market based on complete blood count, hgb/hct tests, basic metabolic panel, bun creatinine tests, electrolytes testing, hba1c tests, comprehensive metabolic panel tests, liver panel tests, renal panel tests, lipid panel tests covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of cardiovascular diseases and rising awareness about diseases are among the factors driving the market. According to ScienceDirect, by 2035, the prevalence of CVDs is estimated to reach approximately 479,500. Similarly, according to the International Diabetes Atlas, in 2021, over 4,274.1 per 1,000 people in the country had diabetes.
Chronic diseases need constant support from clinical laboratories for making treatment possible, and thus, their growing prevalence is creating growth opportunities. Saudi Arabia has conducted the highest number of COVID-19 tests in the region; over 45.2 million tests were conducted by March 2023, showcasing its strong clinical laboratory tests network and efficiency.
In April 2020, the country received support from BGI for setting up six Huo-Yan Laboratories, which would facilitate the testing of 30% of its population. Moreover, its deal with China valued at USD 265 million for 9 million tests and 500 experts helped increase testing capacity, improving the diagnostic capacity in the country.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account